We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $21.7B
1-Year Est. Return 79.24%
This Fund
S&P 500
This Quarter Est. Return
+33.18%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$21.7B
AUM Growth
+$2.61B
Cap. Flow
-$3.46B
Cap. Flow %
-15.95%
Top 10 Hldgs %
62.14%
Holding
194
New
19
Increased
30
Reduced
23
Closed
105

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
ROIV icon
Roivant Sciences
ROIV
+$137M
3
IMVT icon
Immunovant
IMVT
+$130M
4
BBIO icon
BridgeBio Pharma
BBIO
+$96.5M
5
BIDU icon
Baidu
BIDU
+$94.1M

Top Sells

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$498M
2
AMZN icon
Amazon
AMZN
+$398M
3
SCHW
Charles Schwab
SCHW
+$372M
4
AON icon
Aon
AON
+$365M
5
GOOG icon
Alphabet (Google) Class C
GOOG
+$286M

Sector Composition

Rank Sector Weight
1 Healthcare 54.84%
2 Miscellaneous 21.83%
3 Communication Services 8.41%
4 Technology 5.7%
5 Financials 3.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TWST icon
26
Twist Bioscience
TWST
$8.47B
$220M 1.01%
2,136,400
+708,750
+50% +$46.1M
AGIO icon
27
Agios Pharmaceuticals
AGIO
$1.98B
$220M 1.01%
5,917,400
+233,400
+4% +$7.08M
ARMK icon
28
Aramark
ARMK
$15.1B
$206M 0.95%
3,625,731
-2,509,700
-41% -$124M
BIDU icon
29
Baidu
BIDU
$32.4B
$138M 0.63%
1,203,785
+760,000
+171% +$94.1M
NVO
30
Novo Nordisk
NVO
$210B
$126M 0.58%
2,619,000
+1,837,000
+235% +$78.9M
ACHC icon
31
Acadia Healthcare
ACHC
$2.64B
$125M 0.58%
4,220,800
+2,484,000
+143% +$63.8M
BTSG icon
32
BrightSpring Health Services
BTSG
$12.2B
$121M 0.56%
1,732,800
+115,800
+7% +$6.43M
AZN icon
33
AstraZeneca
AZN
$256B
$109M 0.5%
574,000
+347,501
+153% +$65.4M
JNJ icon
34
Johnson & Johnson
JNJ
$671B
$104M 0.48%
408,000
+260,000
+176% +$60.6M
SOXX icon
35
PUT
iShares Semiconductor ETF
SOXX
$41.3B
$83.3M 0.38%
+130,000
New +$66M
PBLS
36
Parabilis Medicines Inc
PBLS
$5.03B
$64.8M 0.3%
+2,368,200
New +$65.4M
NVS icon
37
Novartis
NVS
$310B
$56.9M 0.26%
+363,000
New +$54.4M
GH icon
38
Guardant Health
GH
$21.6B
$48.3M 0.22%
322,200
+314,200
+3,928% +$34.2M
AVTX icon
39
Avalo Therapeutics
AVTX
$1.02B
$46.2M 0.21%
2,498,000
+1,582,000
+173% +$25M
JOYY
40
JOYY Inc
JOYY
$3.65B
$46.1M 0.21%
699,200
+121,000
+21% +$7.53M
ASMB icon
41
Assembly Biosciences
ASMB
$736M
$44.1M 0.2%
1,604,590
+377,000
+31% +$10.3M
ENTA icon
42
Enanta Pharmaceuticals
ENTA
$408M
$35.3M 0.16%
2,418,202
-453,660
-16% -$6.1M
MAZE
43
Maze Therapeutics
MAZE
$1.44B
$33.1M 0.15%
1,107,814
+734,814
+197% +$19.3M
CGON icon
44
CALL
CG Oncology
CGON
$6.59B
$28.4M 0.13%
400,000
+200,000
+100% +$13.1M
MRK icon
45
Merck
MRK
$376B
$25.6M 0.12%
199,000
-162,000
-45% -$19M
WRBY icon
46
Warby Parker
WRBY
$2.88B
$25.1M 0.12%
+828,000
New +$20.5M
PCSC
47
DELISTED
Perceptive Capital Solutions
PCSC
$24.5M 0.11%
2,250,000
– –
KLRA
48
Kailera Therapeutics
KLRA
$2.04B
$24.2M 0.11%
+1,100,000
New +$24.2M
RIO icon
49
Rio Tinto
RIO
$167B
$17.4M 0.08%
183,475
+129,675
+241% +$13.1M
AXTA icon
50
Axalta
AXTA
$7.7B
$16.4M 0.08%
+478,000
New +$14.4M
1
2
3 4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Farallon Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Farallon Capital Management held 194 positions worth $21.7B, up 14% from $19.1B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Farallon Capital Management withdrew a net $3.46B in Q2 2026, closing 105 positions and reducing 23 holdings. Its most notable exit was Charles Schwab, an estimated $372M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, up from 47% a quarter earlier, followed by Miscellaneous and Communication Services.

Against the trend, Farallon Capital Management opened a new position in Parabilis Medicines Inc worth $64.8M.

  • Farallon Capital Management's largest Q2 2026 buy was Parabilis Medicines Inc: 2,368,200 shares worth $64.8M.
  • Farallon Capital Management added most to Boston Scientific in Q2 2026, an estimated $166M increase.
  • Farallon Capital Management's biggest Q2 2026 reduction was Microsoft, cutting an estimated $498M.
  • Farallon Capital Management fully exited Charles Schwab in Q2 2026, selling an estimated $372M.
  • Farallon Capital Management's ten largest holdings make up 62% of its $21.7B portfolio in Q2 2026.
  • Farallon Capital Management opened 19 new positions and closed 105 in Q2 2026.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $21.7B.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.